Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced a collaboration with Thermo Fisher Scientific, a leading international pharmaceutical and laboratory equipment supplier, to integrate the two platforms to provide seamless automation of biopharma R&D operations. The combined platform directly imports raw instrument data from Thermo Fisher Scientific instruments into the Genedata platform, where the data can be processed and interpreted with all other data collected along the entire biopharma R&D workflow. The centralized platform makes it possible for scientists to integrate and digitalize automation systems for sample handling, lab operations, and testing, and digitally trace all results for every sample to make data-driven decisions that expedite R&D breakthroughs.
“Our collaboration with Genedata will enable biopharma companies to fully integrate R&D automation platforms for the direct capture, processing, and analysis of the large amount of data being produced by today’s high-throughput robotic systems. Scientists can now do more experiments in a shorter time and maximize their lab automation investments,” said Hansjoerg Haas, Senior Director, Lab Automation, Thermo Fisher Scientific. “By bringing together Thermo Fisher’s automation systems and the Genedata Biopharma platform, all molecule, sample, assay, and analytics data across both instruments and processes are fully integrated, enabling traceability for molecules, samples, results, and processes. This gives researchers the power to make data-based decisions and uncover insights not possible before.”
Thermo Fisher and Genedata are implementing standard integration interfaces to easily set up and operate Thermo Fisher’s lab equipment and robotics with the Genedata Biopharma platform, which acts as a workflow backbone connecting all information from early discovery to development. The newly integrated platform supports complex sub-workflows such as cherry picking, plasmid construction, antibody expression and expansion, and plasmid and antibody purification, and drives significant efficiency gains along the full biopharma R&D workflow. The integration includes both Thermo Fisher laboratory instruments and Thermo Fisher Momentum software.
“We are pleased to welcome Thermo Fisher as our latest lab automation Ready-to-Run™ partner,” said Othmar Pfannes, Ph.D., CEO of Genedata. “Biopharmaceutical and biotech companies already automate complex laboratory workflows using our seamless integration with lab equipment from many major instrument providers. Our customers expect data traceability across the entire biopharma R&D workflow and by further automating integration of lab instrument data, we are providing a central and structured database for every experimental sample, result, and process. This supports the growing demand for data-driven drug discovery.”
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
LinkedIn | Twitter | YouTube
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.